Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage oncology-focused biotechnology company that develops biologic medicines with single or bispecific action. The company's proprietary fully human albumin binding technology utilizes human single chain antibodies fragment to hitch-hike on human serum albumin for transport to target tissues. Its lead candidate, SON-1010, is a fully human version of interleukin 12 for non-small cell lung cancer and head and neck cancer treatment. Additionally, SON-080, a fully human version of interleukin 6, is being developed for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. The company also has a license agreement for the development and commercialization of pharmaceutical preparations containing a specific recombinant human interleukin 6.

Products

• Biologic medicines with single or bispecific action